Abbott Laboratories (ABT) Financials
PeriodQ2 FY2026
Published
Abbott Laboratories reported $12.59 billion in net sales for Q2 FY2026, the quarter ended June 30, 2026, up 13.0% from a year earlier, as the Exact Sciences cancer diagnostics business acquired in March 2026 added to the Diagnostic Products segment. Earnings moved the other way: net earnings were $928 million, down 47.8%, and diluted EPS was $0.53 against $1.01 a year earlier, with acquisition-related intangible amortization, integration expense, higher legal reserves, interest on the debt raised for the acquisition and a higher tax charge all weighing on the result. Operating earnings were $1.69 billion, down 17.5%, while Medical Devices, Abbott's largest segment, had sales of $5.85 billion, up 9.0%.
| Metric | Amount | vs. year ago |
|---|---|---|
| Revenue | $12,593,000,000 | up 13.0% |
| Net income | $928,000,000 | down 47.8% |
| Diluted EPS | $0.53 | down 47.5% |
| Operating earnings | $1,693,000,000 | down 17.5% |
| Medical Devices sales | $5,853,000,000 | up 9.0% |
Company details
| Name | Abbott Laboratories |
|---|---|
| Ticker | ABT |
| CIK | 0000001800 |
| Exchange | NYSE |
| State | Illinois |
| Incorporation | Illinois |
| SIC | 2834 |
| Office | Life Sciences |
| Industry | Pharmaceutical Preparations |
| Latest period covered | Q2 FY2026, ended 2026-06-30, 10-Q, accession 0001628280-26-050134 |
| Fiscal year end | 12/31 (MM/DD) |
| Next expected filing | 10-Q around 2026-10-28 (predicted) |
Data files
- Financial statementsPage Annual financial statements plus the latest quarter: income statement, balance sheet, cash flow. Actual dollars, actual shares. Sourcing notes and uncertainties included.
- 10-K and 10-Q summaryPage Qualitative synthesis of the latest 10-K + 10-Q: business, risk factors (quarter-over-quarter changes flagged), MD&A, legal proceedings, subsequent events.
- 8-K filings and eventsPage Digest of material 8-K filings: earnings headlines, management changes, capital-return and financing actions, governance. SEC accession numbers cited throughout.
FAQ · Abbott Laboratories Q2 FY2026
How much revenue did Abbott report in Q2 FY2026?
Abbott Laboratories reported $12.59 billion in net sales for Q2 FY2026, the quarter ended June 30, 2026. That is up 13.0% from $11.14 billion in the same quarter a year earlier, growth that includes the Exact Sciences business acquired in March 2026.
What was Abbott's earnings per share in Q2 FY2026?
Abbott Laboratories reported diluted earnings per share of $0.53 for Q2 FY2026, the quarter ended June 30, 2026, against $1.01 in the same quarter a year earlier. Net earnings for the quarter were $928 million, down 47.8%.
Why did Abbott's profit fall in Q2 FY2026?
Abbott Laboratories earned $928 million in Q2 FY2026, down 47.8% from $1.78 billion a year earlier, even though net sales rose. Operating earnings were $1.69 billion, down 17.5%, held back by intangible amortization and integration expense from the Exact Sciences acquisition and by higher legal reserves, and the rest of the decline came below the operating line from interest on the acquisition debt and a higher tax charge.
How much did Abbott's Medical Devices segment sell in Q2 FY2026?
Abbott Laboratories' Medical Devices segment, its largest business, had net sales of $5.85 billion in Q2 FY2026, the quarter ended June 30, 2026, up 9.0% from $5.37 billion a year earlier.
Where can I get Abbott Laboratories (ABT) financial data in machine-readable form?
Ticker Scout publishes Abbott Laboratories's financial statements as JSON at https://tickerscout.ai/abt/financials.json, free, with no API key and no signup. The 10-K and 10-Q narrative and the 8-K events digest are published as Markdown at https://tickerscout.ai/abt/narrative.md and https://tickerscout.ai/abt/events.md. Abbott Laboratories's SEC CIK is 0000001800. Every figure cites the SEC accession number it came from, so it can be checked against sec.gov.
When does Abbott Laboratories (ABT) next file with the SEC?
Abbott Laboratories (ABT) is expected to file its next Form 10-Q with the SEC on or around October 28, 2026. That date is a projection rather than a company-announced date: it is derived from Abbott Laboratories's own filing history with the SEC, by taking the date the company filed the same fiscal period a year earlier and adding 52 weeks. The most recent periodic report on file is the 10-Q for Q2 FY2026, the period ended 2026-06-30, SEC accession 0001628280-26-050134.
Related companies
How this page was built
This page was built from Abbott Laboratories's own filings with the SEC, read one at a time, and nothing on it is taken from a pre-tagged dataset, a data vendor or another website. The figures are on the company's own fiscal calendar and in actual dollars, as the filings report them. Where the filings do not support a figure, the record says so instead of reporting a zero; this period names four such gaps.
A single company files thousands of pages with the SEC in a year, and no two companies file them the same way, so the reading and the assembly here are done by AI rather than by rules that break on the differences. Every pass is then audited back against the filings it came from before the page is published, and anything the filings do not support is left out and named rather than filled in. AI can still make mistakes. That is why the accession numbers are printed: the filing is the authority, and this page is a route to it.
Published by Ticker Scout, an independent publisher of company filings data. About Ticker Scout · Disclaimer
Data extracted from SEC filings (accession numbers cited in each file). The undated URLs hold the latest period and are replaced in place each quarter; every period also stays published at its own dated URL, which never changes. Free to cite with attribution: Ticker Scout (tickerscout.ai). Not investment advice, see the Disclaimer.